Rachael A Mccloy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1336881/publications.pdf

Version: 2024-02-01

24 papers

1,474 citations

623734 14 h-index ⁷⁵²⁶⁹⁸
20
g-index

30 all docs 30 docs citations

30 times ranked

4007 citing authors

#	Article	IF	CITATIONS
1	Activin-A, Growth Differentiation Factor- 11 and Transforming Growth Factor- \hat{l}^2 as predictive biomarkers for platinum chemotherapy in advanced non-small cell lung cancer. Cancer Treatment and Research Communications, 2022, 32, 100576.	1.7	1
2	SILAC kinase screen identifies potential MASTL substrates. Scientific Reports, 2022, 12, .	3.3	3
3	Retinal ganglion cell-specific genetic regulation in primary open-angle glaucoma. Cell Genomics, 2022, 2, 100142.	6.5	9
4	A non-genetic, cell cycle-dependent mechanism of platinum resistance in lung adenocarcinoma. ELife, 2021, 10, .	6.0	14
5	Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma. ELife, 2020, 9, .	6.0	7
6	Activin as a biomarker for platinum resistance in non-small cell lung cancer Journal of Clinical Oncology, 2020, 38, e21737-e21737.	1.6	0
7	Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer. Oncogene, 2019, 38, 1661-1675.	5.9	26
8	Using single cell genomics to change the treatment of lung cancer Journal of Clinical Oncology, 2019, 37, e20563-e20563.	1.6	0
9	The tumor suppressor Hic1 maintains chromosomal stability independent of Tp53. Oncogene, 2018, 37, 1939-1948.	5.9	18
10	Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. Science Translational Medicine, $2018,10,.$	12.4	32
11	MASTL overexpression promotes chromosome instability and metastasis in breast cancer. Oncogene, 2018, 37, 4518-4533.	5.9	45
12	The E3 ubiquitin ligase UBR5 regulates centriolar satellite stability and primary cilia. Molecular Biology of the Cell, 2018, 29, 1542-1554.	2.1	27
13	Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 2017, 9, .	12.4	208
14	PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells. Journal of Cell Science, 2016, 129, 1340-54.	2.0	44
15	Mechanisms regulating phosphatase specificity and the removal of individual phosphorylation sites during mitotic exit. BioEssays, 2016, 38, S24-32.	2.5	26
16	Mechanisms regulating phosphatase specificity and the removal of individual phosphorylation sites during mitotic exit. Inside the Cell, 2016, 1, 27-35.	0.4	0
17	Dataset from the global phosphoproteomic mapping of early mitotic exit in human cells. Data in Brief, 2015, 5, 45-52.	1.0	8
18	Global Phosphoproteomic Mapping of Early Mitotic Exit in Human Cells Identifies Novel Substrate Dephosphorylation Motifs. Molecular and Cellular Proteomics, 2015, 14, 2194-2212.	3.8	63

#	Article	IF	CITATION
19	Partial inhibition of Cdk1 in G ₂ phase overrides the SAC and decouples mitotic events. Cell Cycle, 2014, 13, 1400-1412.	2.6	773
20	Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. FEBS Journal, 2013, 280, 5237-5257.	4.7	36
21	BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer. Molecular Cancer Therapeutics, 2013, 12, 1874-1885.	4.1	45
22	Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells. British Journal of Cancer, 2013, 109, 3034-3041.	6.4	14
23	Tamoxifen-Induced Epigenetic Silencing of Oestrogen-Regulated Genes in Anti-Hormone Resistant Breast Cancer. PLoS ONE, 2012, 7, e40466.	2.5	54
24	Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene, 2011, 30, 3186-3197.	5.9	21